Wall Street brokerages forecast that LeMaitre Vascular Inc (NASDAQ:LMAT) will post earnings per share of $0.19 for the current quarter, according to Zacks. Two analysts have made estimates for LeMaitre Vascular’s earnings. The highest EPS estimate is $0.20 and the lowest is $0.19. LeMaitre Vascular posted earnings per share of $0.13 in the same quarter last year, which suggests a positive year-over-year growth rate of 46.2%. The company is scheduled to announce its next quarterly earnings results on Tuesday, February 20th.
On average, analysts expect that LeMaitre Vascular will report full-year earnings of $0.84 per share for the current fiscal year. For the next financial year, analysts expect that the firm will report earnings of $0.87 per share, with EPS estimates ranging from $0.79 to $0.93. Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that cover LeMaitre Vascular.
LeMaitre Vascular (NASDAQ:LMAT) last issued its earnings results on Thursday, October 26th. The medical instruments supplier reported $0.25 earnings per share for the quarter, topping the consensus estimate of $0.20 by $0.05. LeMaitre Vascular had a net margin of 15.81% and a return on equity of 16.16%. The company had revenue of $24.80 million for the quarter, compared to analyst estimates of $25.49 million. During the same period in the prior year, the business posted $0.17 earnings per share. The firm’s revenue for the quarter was up 6.9% compared to the same quarter last year.
LMAT has been the topic of several research reports. Zacks Investment Research upgraded shares of LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $35.00 price target on the stock in a research report on Thursday. Stifel Nicolaus reiterated a “buy” rating on shares of LeMaitre Vascular in a research report on Sunday, October 29th. BidaskClub lowered shares of LeMaitre Vascular from a “sell” rating to a “strong sell” rating in a research report on Wednesday. Canaccord Genuity reiterated a “hold” rating and issued a $30.00 price target on shares of LeMaitre Vascular in a research report on Monday, October 9th. Finally, Benchmark lowered shares of LeMaitre Vascular from a “buy” rating to a “hold” rating in a research report on Friday, October 27th. One analyst has rated the stock with a sell rating, five have assigned a hold rating and two have issued a buy rating to the stock. The company currently has a consensus rating of “Hold” and an average target price of $32.20.
In related news, insider David B. Roberts sold 4,123 shares of the firm’s stock in a transaction that occurred on Monday, November 6th. The shares were sold at an average price of $32.14, for a total transaction of $132,513.22. Following the sale, the insider now owns 24,482 shares in the company, valued at $786,851.48. The sale was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. 23.70% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP boosted its position in LeMaitre Vascular by 2.8% during the third quarter. Dimensional Fund Advisors LP now owns 995,747 shares of the medical instruments supplier’s stock worth $37,261,000 after acquiring an additional 27,515 shares during the last quarter. Conestoga Capital Advisors LLC boosted its position in LeMaitre Vascular by 51.2% during the third quarter. Conestoga Capital Advisors LLC now owns 854,644 shares of the medical instruments supplier’s stock worth $31,981,000 after acquiring an additional 289,575 shares during the last quarter. Vanguard Group Inc. boosted its position in LeMaitre Vascular by 23.5% during the second quarter. Vanguard Group Inc. now owns 815,580 shares of the medical instruments supplier’s stock worth $25,462,000 after acquiring an additional 155,249 shares during the last quarter. State Street Corp boosted its position in LeMaitre Vascular by 25.2% during the second quarter. State Street Corp now owns 382,824 shares of the medical instruments supplier’s stock worth $11,951,000 after acquiring an additional 77,009 shares during the last quarter. Finally, Allianz Asset Management GmbH boosted its position in LeMaitre Vascular by 4.7% during the third quarter. Allianz Asset Management GmbH now owns 321,820 shares of the medical instruments supplier’s stock worth $12,042,000 after acquiring an additional 14,306 shares during the last quarter. Hedge funds and other institutional investors own 69.24% of the company’s stock.
Shares of LeMaitre Vascular (NASDAQ LMAT) traded down $0.46 on Tuesday, reaching $31.84. 164,816 shares of the company’s stock traded hands, compared to its average volume of 174,827. LeMaitre Vascular has a one year low of $19.82 and a one year high of $39.88. The firm has a market capitalization of $607.81, a price-to-earnings ratio of 41.35, a P/E/G ratio of 2.50 and a beta of 0.55.
The firm also recently declared a quarterly dividend, which was paid on Thursday, December 7th. Stockholders of record on Wednesday, November 22nd were given a $0.055 dividend. The ex-dividend date was Tuesday, November 21st. This represents a $0.22 annualized dividend and a dividend yield of 0.69%. LeMaitre Vascular’s dividend payout ratio is presently 28.57%.
ILLEGAL ACTIVITY NOTICE: This piece of content was first posted by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another domain, it was illegally copied and reposted in violation of international trademark & copyright legislation. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2018/01/13/0-19-eps-expected-for-lemaitre-vascular-inc-lmat-this-quarter.html.
About LeMaitre Vascular
LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company develops, manufactures and markets medical devices and implants used primarily in the field of vascular surgery. It is engaged in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.
Get a free copy of the Zacks research report on LeMaitre Vascular (LMAT)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for LeMaitre Vascular Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LeMaitre Vascular and related companies with MarketBeat.com's FREE daily email newsletter.